课题基金 / 基金详情

项目摘要

项目成果

Frederic Barr的其他基金

相似基金

相关文献

中文摘要
翻译
为了扩展我们在人类RMS肿瘤中DNA甲基化的研究,我们使用Illumina HM450和EPIC阵列来评估几个RMS肿瘤队列的全基因组DNA甲基化模式。无监督分析证实了我们之前的发现,DNA甲基化模式和融合状态密切相关。除了FP和FN类别之间的甲基化差异外,我们的分析还揭示了FP集群中的两个主要子集,以及FN集群中的两个主要子集。特别是,这些研究揭示了P3F和P7F融合在两个FP亚群中的一个中都富集。同样,RAS通路基因(HRAS、NRAS、KRAS、SOS1、NF1)的突变在两个FN亚群中富集或缺失。为了扩展这些发现,我们在P3F和p7f阳性类别之间,以及突变型和野生型RAS通路的FN病例之间寻找甲基化差异的基因。在FP病例中,与p7f阳性肿瘤相比,P3F-中启动子甲基化程度更高的一个值得注意的基因是CDKN1C,这是一种推定的肿瘤抑制基因,位于RMS和其他肿瘤中11p15.5等位基因缺失的区域。RNA和蛋白表达研究显示,与p7f阳性肿瘤相比,P3F-中CDKN1C表达较少。在FN病例中,突变RAS通路肿瘤中启动子甲基化显著降低的一个值得注意的基因是ALDH1A3,该基因先前被报道为FN RMS中癌症干细胞的潜在标记物。RNA表达研究显示,与野生型肿瘤相比,RAS通路突变体中ALDH1A3 mRNA的表达显著升高。为了进一步研究其他甲基化定义的亚群,我们将基因突变数据与FN RMS病例的分层聚类模式进行了比较。值得注意的是,我们确定了一小群MYOD1突变的FN RMS病例紧密聚集在相对缺乏RAS通路突变的FN亚群中。尽管这一FN亚群在统计学上具有较少的RAS通路突变,但MYOD1突变组与该亚群中具有RAS通路突变的许多病例相对应。在第二项分析中,我们扩展了之前的发现,即正常骨骼肌中的DNA甲基化模式比FP病例更类似于FN,我们检查了正常骨骼肌与两个甲基化定义的FN亚群的关系。使用无监督的生物信息学方法,我们确定正常骨骼肌与RAS通路突变中缺失的FN亚群比RAS通路突变中富集的FN亚群更相似。最后,为了确定哪种RMS模型系统最能概括人类原发RMS肿瘤中发现的DNA甲基化模式,我们比较了原发RMS肿瘤与长期RMS细胞系、来自这些长期RMS细胞系的异种移植物(CDXs)和患者来源的异种移植物(PDXs)的全基因组甲基化模式。无监督方法展示了两个主要的FP集群和两个主要的FN集群。在每一对FP或FN簇中,一个包含几乎所有的细胞系和cdx,另一个包含几乎所有的pdx和原发肿瘤。对相关热图的检查显示,绝大多数分析的CpG位点在细胞系和cdx中都是高甲基化的,而在原发肿瘤和pdx中发现的低甲基化和高甲基化分布更广泛。我们没有发现pdx和原发肿瘤之间的总体甲基化水平有统计学差异,而细胞系和cdx的总体甲基化水平明显较高。虽然这些发现表明pdx是研究RMS肿瘤中DNA甲基化模式生物学意义的最佳实验模型,但我们承认pdx不像培养的细胞系那样容易被操纵。由于来自PDX的细胞可以培养,我们随后评估了PDX肿瘤短期培养(1-2个月)时DNA甲基化模式的稳定性。我们的无监督分析比较了RMS PDX肿瘤和一组长期RMS细胞系的短期培养,结果表明,所有FN短期培养和大多数FP短期培养在短期培养期间保持了整体DNA甲基化模式。因此,这些发现提供了在将这些细胞返回体内环境之前使用短期培养对pdx进行实验操作的可能性。
英文摘要
To extend our studies of DNA methylation in human RMS tumors, we used Illumina HM450 and EPIC arrays to assess genome-wide DNA methylation patterns in several cohorts of RMS tumors. Unsupervised analyses confirmed our previous finding of a close association of DNA methylation pattern and fusion status. In addition to the methylation differences between the FP and FN categories, our analysis also revealed two major subsets within the FP cluster, and two major subsets within the FN cluster. In particular, these studies revealed that the P3F and P7F fusions were each enriched in one of the two FP subsets. Similarly, mutations in RAS pathway genes (HRAS, NRAS, KRAS, SOS1, NF1) were enriched or depleted in the two FN subsets. To extend these findings, we searched for genes with differential methylation between the P3F and P7F-positive categories, and between FN cases with mutant and wild-type RAS pathways. In the FP cases, one notable gene with higher promoter methylation in P3F- than P7F-positive tumors is CDKN1C, a putative tumor suppressor gene localized within a region of 11p15.5 allelic loss in RMS and other tumors. RNA and protein expression studies showed less CDKN1C expression in P3F- compared to P7F-positive tumors. In the FN cases, one notable gene with significantly lower promoter methylation in mutant RAS pathway tumors is ALDH1A3, which was previously reported as a potential marker for cancer stem cells in FN RMS. RNA expression studies revealed significantly higher ALDH1A3 mRNA expression in RAS pathway mutant versus wild-type tumors. To further investigate additional methylation-defined subsets, we compared gene mutation data with the hierarchical clustering pattern in our FN RMS cases. Of note, we determined that the small group of FN RMS cases with MYOD1 mutations were tightly clustered within the FN subset that is relatively depleted of RAS pathway mutations. Although this FN subset has statistically fewer RAS pathway mutations, the mutant MYOD1 group corresponded to many of the cases within this subset that had RAS pathway mutations. In a second analysis to extend our previous finding that the DNA methylation pattern in normal skeletal muscle is more similar to FN than FP cases, we examined the relationship of normal skeletal muscle to the two methylation-defined FN subsets. Using unsupervised bioinformatic methodologies, we determined that normal skeletal muscle was more similar to the FN subset depleted in RAS pathway mutations than the subset enriched in RAS pathway mutations. Finally, to determine which RMS model systems best recapitulate the DNA methylation patterns found in human primary RMS tumors, we compared genome-wide methylation patterns in primary RMS tumors to long-term RMS cell lines, xenografts derived from these long-term cell lines (CDXs) and patient-derived xenografts (PDXs). Unsupervised approaches demonstrate two main FP clusters and two main FN clusters. Within each pair of FP or FN clusters, one contains nearly all cell lines and CDXs and the other contains nearly all PDXs and primary tumors. Examination of the associated heat maps reveal that the vast majority of analyzed CpG sites are hypermethylated in cell lines and CDXs in contrast to the wider distribution of hypo- and hypermethylation found in primary tumors and PDXs. We did not find any statistical differences in overall methylation levels between PDXs and primary tumors in contrast to the significantly higher overall methylation levels in cell lines and CDXs. Though these findings indicate that PDXs are the optimal experimental model to study the biological significance of DNA methylation patterns in RMS tumors, we acknowledge that the PDXs cannot be manipulated as easily as cultured cell lines. Since cells from the PDXs can be cultured, we then assessed the stability of the DNA methylation patterns when short-term cultures (1-2 months) were established from the PDX tumors. Our unsupervised analysis comparing RMS PDX tumors and short-term cultures with a set of long-term RMS cell lines showed that the overall DNA methylation pattern was maintained during short-term culture for all FN short term cultures and most FP short term cultures. These findings thus provide the possibility of using a short-term culture to perform experimental manipulations of PDXs before returning these cells to the in vivo environment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
  • 批准号:
    10486830
  • 项目类别:
  • 资助金额:
    $70.45万
  • 财政年份:
    --
  • 负责人:
    Frederic Barr
  • 依托单位:
Studies of amplification in rhabdomyosarcoma
Studies of amplification in rhabdomyosarcoma
Clinical Operations for Laboratory of Pathology
海外基金